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Although the close regional coupling of resting cerebral blood flow (CBF) with both cerebral
metabolic rate of oxygen (CMRO2) and cerebral metabolic rate of glucose (CMRglc) within
individuals is well documented, there are few data regarding the coupling between whole brain
flow and metabolism among different subjects. To investigate the metabolic control of resting whole
brain CBF, we performed multivariate analysis of hemispheric CMRO2, CMRglc, and other covariates
as predictors of resting CBF among 23 normal humans. The univariate analysis showed that only
CMRO2 was a significant predictor of CBF. The final multivariate model contained two additional
terms in addition to CMRO2: arterial oxygen content and oxygen extraction fraction. Notably, arterial
plasma glucose concentration and CMRglc were not included in the final model. Our data
demonstrate that the metabolic factor controlling hemispheric CBF in the normal resting brain is
CMRO2 and that CMRglc does not make a contribution. Our findings provide evidence for
compartmentalization of brain metabolism into a basal component in which CBF is coupled to
oxygen metabolism and an activation component in which CBF is controlled by another mechanism.
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Introduction
There is substantial interindividual variation in
resting whole brain values of cerebral blood flow
(CBF), cerebral metabolic rate of oxygen (CMRO2),
and cerebral metabolic rate of glucose (CMRglc) in
normal humans, with coefficients of variation of 13%
to 23% (Scheinberg and Stead, 1949; Gottstein et al,
1963; Fiorelli et al, 1992; Madsen et al, 1993; Ito et al,
2004; Mosconi et al, 2007). Although the close
regional coupling of resting CBF with both CMRO2
and CMRglc within individuals is well documented,
few data exist regarding the coupling between whole
brain flow and metabolism among different subjects
(Sokoloff, 1981; Lebrun-Grandie et al, 1983; Raichle
et al, 2001; Coles et al, 2006). To investigate the
metabolic control of resting whole brain CBF, we
performed multivariate analysis of hemispheric
CMRO2, CMRglc, and other covariates as predictors
of resting CBF among 23 normal humans.
Materials and methods
Participants
Normal volunteers were recruited as controls for a study of
cerebral metabolism in patients with Huntington and
Parkinson diseases (Powers et al, 2007, 2008). They were
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recruited by public advertisement and from friends and
spouses of patients. All underwent clinical neurologic
evaluation by a neurologist.
Inclusion criteria were the following:
1. Disease free by subject’s own history including no
history of migraine, childhood febrile seizures, or head
trauma with loss of consciousness
2. Taking no medication by subject’s own history
3. No signs or symptoms of neurologic disease other than
mild distal sensory loss in the legs consistent with age
4. No pathological lesions on magnetic resonance (MR)
scan performed for this study (see below). Mild atrophy
and punctate asymptomatic white matter abnormalities
were not considered pathological
Exclusion criteria were the following:
1. Younger than 18 years
2. Major neurologic or psychiatric disease or clinically
significant lesions on brain imaging that was performed
before enrollment in the study
3. Regular treatment or exposure in the last 6 months to
neuroleptics, metoclopramide, alphamethyldopa, cloza-
pine, olanzapine, quetiapine, flunarizine, cinnarizine,
reserpine, amphetamines, monoamine oxidase inhibi-
tors (MAO), or other medications that might interfere
with mitochondrial metabolism
4. Ever having taken dopaminergic medications
5. Anticholinergics, amantadine, CoQ10, selegiline, and
vitamins E and C must be discontinued for 30 days
before entry into the study
6. Diabetes mellitus treated by medications
7. Pregnancy
Image Acquisition
High-resolution T1-weighted MR images were acquired
with a Siemens Magnetom SONATA 1.5T scanner (Siemens
Medical Solutions USA, Inc., Malvern, PA, USA). A
midsagittal scout spin-echo sequence was used to
position the subject, then a 3D MPRAGE sequence was
acquired (repetition time (TR)/echo time (TE)/inversion
time (TI) = 1900/3.93/1100 milliseconds, flip angle (FA) = 81,
7:07 minutes, 128 256 256 matrix 1.25 1 1 mm3
voxels).
Positron emission tomography (PET) images were ob-
tained in the 2D acquisition mode, with a Siemens/CTI
ECAT EXACT HR 47 PET scanner (Siemens Medical
Solutions USA, Inc.), with participants lying supine in a
quiet dark room. A single transmission scan using
68Ge/68Ga rotating rod sources was performed before
radiotracer administration and used for subsequent at-
tenuation correction of all emission data. Emission data
were acquired in the 2D mode because of the problems that
we and others have experienced with the scatter correction
when trying to acquire 3D O15O images (Coles et al, 2006).
Cerebral blood volume (CBV) data were acquired with a 5-
min emission scan beginning 2 min after brief inhalation of
75 mCi of C15O (Martin et al, 1987). Cerebral metabolic rate
of oxygen and oxygen extraction fraction (OEF) data were
acquired with a 40-second emission scan after brief
inhalation of 75 mCi of O15O (Mintun et al, 1984). Cerebral
blood flow data were acquired with a 40-second emission
scan after rapid injection of 50 mCi H2
15O in saline (Raichle
et al, 1983). During these 15O studies, arterial blood was
withdrawn at 5 mL/min from the radial artery through
narrow bore tubing to a lead shielded scintillation detector
that measures positron emissions with 1 second temporal
resolution. These arterial blood radioactivity measure-
ments were corrected for delay and dispersion in the
tubing using parameters empirically determined in a
previous experimental study. This study used the same
tubing and the same withdrawal pump with human blood
of differing hematocrits. 15O radiolabeled blood was placed
in one-half of a chamber separated from nonradioactive
water by a rubber membrane. Liquid withdrawal was
begun from the nonradioactive side through the tubing to
the lead shielded scintillation detector. A timed square
wave of radiolabeled blood was generated by quickly
puncturing the rubber membrane. The delay and disper-
sion parameters necessary to convert the resultant time–
radioactivity curves recorded by the detector back to the
original square wave were empirically determined as a
function of hematocrit. The time shift between arrival of
radioactivity in the sampled arterial blood and in the brain
was determined during the H2
15O scan by the sudden
increase in total coincidence events in the field-of-view as
recorded at 1 second interval by the scanner. Data for
measurement of the CMRglc were obtained after slow
intravenous injection of 10 mCi of 18F-fluorodeoxyglucose
(18FDG) over 10 to 20 seconds. Dynamic PET acquisition
began with injection and continued for 60 minutes accord-
ing to the following scheme: 16 30-second frames, 8
1-minute frames, 16 2-minute frames, and 4 3-minute
frames. During this period, blood samples were hand-
drawn frequently from the arterial catheter and counted in
a well counter. Arterial samples for plasma glucose
determination were obtained just before, at the midpoint
during and at the end of the scan and the mean was
determined. Plasma glucose was determined by the glucose
oxidase method in the Department of Laboratories, Barnes-
Jewish Hospital. Arterial blood samples for the measure-
ment of arterial partial pressure of oxygen, arterial partial
pressure of carbon dioxide, arterial hemoglobin concentra-
tion, and arterial oxygen content were collected twice
during the scan session, usually at the beginning before the
C15O scan and again after the 18FDG scan (Instrumentation
Laboratory, Lexington, MA, USA). Hematocrit was deter-
mined by microcentrifugation. The scanner was calibrated
to the well counter for conversion of PET counts to
quantitative radiotracer concentrations using a cylindrical
phantom. All PET emission scans were reconstructed with
filtered back projection using the individual attenuation
measurements and scatter correction with a ramp filter
cutoff at the Nyquist frequency, producing images with a
resolution of 4.3 mm full width at half maximum.
Image Analysis
The MR image was segmented by first plotting histograms
of the voxel intensities of cortical gray matter and
ventricular cerebrospinal fluid (CSF). The threshold
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intensity separating brain from CSF was chosen as the
midpoint between gray matter and CSF peaks. Voxels
below this intensity and voxels not connected in 3D to a
seed point within each brain removed most nonbrain
voxels. Manual editing was required to remove external
tissue where there was insufficient CSF to separate the
brain (near sinuses, temporal lobes, eyes, and brainstem),
and a single erosion followed by conditional dilation
completed the tissue segmentation. The MR image was
then edited manually to generate a region of interest
encompassing both cerebral hemispheres by removing the
cerebellum and brainstem along a plane connecting the
posterior commissure and the most inferior point of the
interpeduncular fossa (Filipek et al, 1994).
The original segmented MR image plus the three 15O PET
images were coregistered to a composite 40 to 60 minutes
18FDG PET image using Automated Image Registration
software (AIR, Roger Woods, University of California, Los
Angeles, CA, USA) (Woods et al, 1993) A binary tissue
image was created from the original segmented MR image
(voxels values of 1 representing brain and 0 representing
nonbrain) and convolved to the 3D resolution of the PET
images. This convolved tissue image defines the fractional
tissue contribution for the measured PET activity in each
voxel and was used to correct the radioactivity measure-
ment in each PET image for partial volume effects due to
nonbrain structures including CSF (Videen et al, 1999).
Partial volume-corrected mean counts were generated for
the bihemispheric regions of interest for each of the three
15O PET images and for the dynamic 18FDG PET images.
Corrected mean counts were converted to quantitative CBF,
OEF, or CMRO2 using previously described methods
(Videen et al, 1987).
For 18FDG, a modified Marquardt parameter estimation
routine was used to derive bihemispheric rate constants
for each participant using the partial volume-corrected
dynamic mean PET counts and arterial whole blood time–
radioactivity curves. We used the standard two-tissue
compartment 18FDG model (Herscovitch, 2002). Five
parameters were estimated: four rate constants (k1, k2, k3,
k4) and the time shift (T0). The flux from compartment 2 to
compartment 1 was treated mathematically as direct egress
from the field of view. The value for the time shift between
arrival of radioactivity in the sampled arterial blood and in
the brain measured from the H2
15O scan was used as the
starting value for this parameter. The volume of compart-
ment 1 was fixed equal to the measured regional CBV. Our
method for measuring CBV assumes a fixed value of 0.85
for the large vessel to small vessel hematocrit ratio (Martin
et al, 1987). Lammertsma et al (1987) have determined that
even 20% errors in this assumed value have little influence
on the calculation of CMRglc. Bihemispheric CMRglc was
calculated as (Glcwb/LC)((K1  k3)/(k2 + k3)), where Glcwb is
the whole blood glucose concentration (micromol/mL), LC
is the lumped constant and K1 = CBV  k1 (Powers et al,
1995; Herscovitch, 2002). As the parameter estimation was
based on whole blood time–radioactivity data, we used
glucose concentrations of whole blood calculated as the
plasma concentration [1(0.30hematocrit] (Powers
et al, 1995). For this study, we computed the LC that
yielded a mean bihemispheric value for CMRO2/CMRglc
equal to the value of 5.6 that has been directly measured
from arterial and jugular venous samples in normal adults,
ages 21 to 69 years (Gottstein et al, 1963). For this
calculation, we used our entire series of 23 normal control
subjects ages 23 to 70 years and calculated an LC = 0.64.
Statistical Analysis
Pearson bivariate correlation coefficients for CBF versus
CMRO2 and CBF versus CMRglc were calculated using
SPSS 16.0 for Windows (SPSS, Inc., Chicago, IL, USA). In
addition, we performed an initial univariate analysis based
on simple linear regression with candidate covariates as
predictors and resting whole brain CBF (mL/100 g per
minute) as the outcome. More specifically, we consider the
model CBF = b0 + b1PREDICTOR for the candidate predictor
variables. When the results of the univariate analysis
(Table 1) indicated that CMRO2, but not CMRglc was
associated with resting whole brain CBF, we also per-
formed a multiple regression analysis to determine if
similar results were obtained after controlling for the
presence of the other covariates. We constructed an initial
linear model containing only CMRO2, and forward selec-
tion was used to determine if additional variables should
be added to create a multiple regression model. Wald test
statistics are often used when performing model selection,
but the asymptotic w2 distribution may not be appropriate
here because of the small sample size. For this reason, we
used the bootstrap approach described by Fox for assessing
the significance of the observed Wald-like statistics in a
nonparametric manner (Fox, 2002). For each hypothesis
being tested, an empirical null distribution was created by
repeatedly computing Wald-like statistics based on multi-
ple regression models in which the response vector and
design matrix are formed by taking bootstrap samples of
the rows of the observed response vector and design
Table 1 Univariate analysis with cerebral blood flow as the
outcome and the candidate predictor variables as covariates












CAglc, arterial glucose concentration (mg/100 mL); CAHgb, arterial hemoglo-
bin concentration (g/100 mL); CAO2, arterial oxygen content (mL O2/100 mL
blood); CMRglc, cerebral metabolic rate of glucose (micromol/100 g per
minute); CMRO2, cerebral metabolic rate of oxygen (micromol/100 g per
minute); Hct, hematocrit; male, binary variable with 1 for males and 0 for
females; OEF, oxygen extraction fraction; pACO2, arterial partial pressure of
carbon dioxide (mm Hg); pAO2, arterial partial pressure of oxygen (mm Hg).
The second column gives parameter estimates for b1 for each predictor, and
the final column shows the P values associated with the tests of H0: b1 = 0
versus Ha: b1 0.
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matrix. Because the binary variable ‘male’ could lead to
design matrices with less than full rank under bootstrap
resampling, this variable was not considered in this
portion of the analysis. The empirical distributions were
based on 5,000 bootstrap samples, and at each stage the
most significant variable was added to the model. Variables
were added to the model if they were significant at the
P = 0.05 level, up to a maximum of four variables. R 2.7.1
was used for these statistical analyses (R Development Core
Team, 2010).
This protocol received prior approval by the Washington
University Human Studies Committee (Institutional
Review Board) and Radioactive Drug Research Committee.
Informed consent was obtained from each subject.
Results
Thirty-three normal control subjects were initially
enrolled in the combined study of Huntington
disease and Parkinson disease. Ten did not success-
fully complete PET and MR studies: eight due to
technical problems, one had an abnormal MR scan,
and one withdrew after MR. The technical problems
were caused by inability to place radial arterial
catheter (3), malfunction of blood scintillation
detector (2), radiochemical contamination of C15O
(1), subcutaneous injection of 18FDG and poor
parameter estimation fit (1). Data from the 23 who
successfully completed PET and MR studies are
presented here. The median age was 55 years (range
23 to 70 years). Thirteen were men. There was a
statistically significant correlation between CBF and
CMRO2 (r = 0.599, P = 0.003) but not between CBF
and CMRglc (r = 0.333, P = 0.120) (Figures 1 and 2).
The univariate analysis (Table 1) showed that
only CMRO2 was a significant predictor of CBF.
The final multivariate model contained two terms in
addition to CMRO2: arterial oxygen content and OEF
(Table 2).
Discussion
In measuring CMRglc with 18FDG, we calculated a
value for the LC = 0.64 based on a CMRO2/CMRglc
ratio equal to the value of 5.6 that has been directly
measured from arterial and jugular venous samples
in normal adults, ages 21 to 69 years (Gottstein et al,
1963). Since this linear scalar was applied to all 23
subjects, use of a different value would not change
the results of the correlation analysis. We used a
method that corrects for artifactual alterations in PET
measurements due to partial volume effects from
individual differences in ventricular and sulcal CSF
volume. Since this linear scalar was applied to each
of the three PET measurements for each individual,
inaccuracies in this computation would have not
affected the results of the correlation analysis. The
CBF method that we used assumes a fixed value for
the partition coefficient of water. Computer simula-
tions have shown that the calculated CBF values are
insensitive to variation in this value with resultant
errors of < 4% (Herscovitch et al, 1983). This method
has been shown to be accurate versus the reference
standard of intracarotid injection of the range of
CBF values of 27 to 59 mL/100 g per minute (Raichle
et al, 1983). The CMRO2 method that we have
used has been validated for quantitative accuracy
PET CMRO2
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Figure 1 Bivariate plot of resting bihemispheric cerebral blood
flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) from
23 normal human volunteers (r = 0.599, P = 0.003).
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Figure 2 Bivariate plot of resting bihemispheric cerebral blood
flow (CBF) and cerebral metabolic rate of glucose (CMRglc) from
23 normal human volunteers (r = 0.333, P = 0.120).







CAO2, arterial oxygen content (mL O2 /100 mL blood); CMRO2, cerebral
metabolic rate of oxygen (micromol/100 g per minute); OEF, oxygen extraction
fraction.
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in nonhuman primates across a wide range of
CMRO2 (Mintun et al, 1984; Altman et al, 1991). It
utilizes the measurement of CBF in the calculation of
OEF and again for the calculation of CMRO2 as the
product of CBF, OEF, and arterial oxygen content. As
the PET CMRO2 measurement is dependent on the
PET CBF measurement whereas the PET CMRglc
measurement is not, we considered the possibility
that there was a methodologic explanation for the
results that we obtained. To address this issue, we
identified two published series of normal whole
brain resting CBF, CMRO2, and CMRglc using
different methodology (Scheinberg and Stead, 1949;
Gottstein et al, 1963). Both of these studies used the
Kety–Schmidt method, which uses measurements
of whole brain CBF together with arterial–jugular
venous substrate differences to calculate CMRO2 and
CMRglc. Using the same analysis methods described
in this paper, both the Gottstein and the Scheinberg
and Stead data sets yield the same conclusion as our
study data. Scheinberg and Stead report initial
resting supine data for CBF, CMRO2, and CMRglc
for 18 subjects ages 21 to 36 years that yield a
statistically significant correlation between CBF and
CMRO2 (r = 0.762, P < 0.001) but not between CBF
and CMRglc (r = 0.183, P = 0.467) (Scheinberg and
Stead, 1949). Gottstein et al (1963) report resting data
for CBF, CMRO2, and CMRglc for 32 normal subjects
ages 21 to 69 years. Their data also provide a
statistically significant correlation between CBF
and CMRO2 (r = 0.497, P = 0.004) but not between
CBF and CMRglc (r = 0.281, P = 0.119). The signifi-
cant correlation coefficients for CBF and CMRO2 of
0.762 and 0.497 are similar to the value of 0.599 that
we obtained. Similarly, the nonsignificant correla-
tion coefficients for CBF and CMRglc of 0.183 and
0.281 are similar to the value of 0.333 that we
obtained. For both of the Kety–Schmidt data sets in
the univariate analysis, the association between CBF
and CMRO2 is significant at the a= 0.05 level, but the
association between CBF and CMRglc is not. Again
for both of the data sets, when performing multiple
regression, CMRglc is not significant at the a= 0.05
level when the model already contains CMRO2.
Thus, the results that we report are confirmed by
totally different methodology.
We calculated the coefficient of variation for our
CBF and CMRO2 data and compared it with a
published compendium of normal data from 11
PET centers (Ito et al, 2004). For CBF, our coefficient
of variation was 18%, within the published range of
5% to 23%. For CMRO2, our coefficient of variation
was 21%, within the published range of 6% to 25%.
For CMRglc, our coefficient of variation was 17%.
This is similar to published values of 16% and
16.5% for whole brain CMRglc data obtained from
parameter estimation (Fiorelli et al, 1992; Mosconi
et al, 2007). The coefficients of variation for the two
sets of Kety–Schmidt data we analyzed are the
following: CBF 21% and 12%, CMRO2 13% and
13%, CMRglc 21% and 13% (Scheinberg and Stead,
1949; Gottstein et al, 1963). As the variability in our
data is very similar to data reported by others, it is
most likely due to a combination of biological and
methodological factors that are not unique to our
specific methodology or subjects.
Two previous studies have reported statistically
significant interindividual correlations between CBF
and CMRO2 for both whole brain and regional values
(Lebrun-Grandie et al, 1983; Coles et al, 2006). We
have not found any previous report of the lack of
interindividual correlation between CBF and
CMRglc. Our final multivariate model included two
terms in addition to CMRO2: arterial oxygen content
and OEF. Both influence oxygen delivery at the
cellular level. Notably, arterial plasma glucose con-
centration and CMRglc were not included in the final
model, indicating that neither glucose supply nor
metabolism was a determinant of CBF. Our data
demonstrate that the metabolic factor controlling
hemispheric CBF in the normal resting brain is
CMRO2 and that CMRglc does not make a contribu-
tion. This is different from the state of brain
activation in which changes in CBF are more closely
correlated to changes in CMRglc than CMRO2,
although the mechanism for this coupling is unlikely
to be the change in CMRglc itself (Fox et al, 1988;
Madsen et al, 1995; Powers et al, 1996; Vlassenko
et al, 2006). Our findings provide evidence for
compartmentalization of brain metabolism into a
basal component in which CBF is coupled to oxygen
metabolism and an activation component in which
CBF is controlled by another mechanism (Nemoto
et al, 1994; Raichle et al, 2001; Lindauer et al, 2010).
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